基于肠道激素治疗肥胖和2型糖尿病的研究进展  

Advances in the treatment of obesity and type 2 diabetes based on intestinal hormones

作　　者：郑珊珊 赵娜[2] 马建[1,2] ZHENG Shanshan;ZHAO Na;MA Jian(Heilongjiang University of Chinese Medicine,Harbin,Heilongjiang 150040,China;不详)

机构地区：[1]黑龙江中医药大学,黑龙江哈尔滨150040 [2]黑龙江中医药大学附属第一医院内分泌科,黑龙江哈尔滨150040

出　　处：《中国临床研究》2025年第2期299-303,共5页Chinese Journal of Clinical Research

基　　金：黑龙江省中医药科研项目(ZYW2022-024)。

摘　　要：基于肠道激素研发的受体激动剂已被证明是目前治疗肥胖和2型糖尿病(T2DM)的有效手段之一,具备良好的应用前景,其治疗机制涉及调节能量平衡及改善胰岛功能等诸多方面。肠道激素作为调节能量平衡的重要物质,在多种组织中通过不同的信号通路对体重和血糖稳态起到调控作用,说明肠道激素在肥胖和T2DM发生发展中具有复杂的调控机制。因此,肠道激素作为肥胖和T2DM治疗靶点的研究引起广泛关注。故本文对当前肠道激素作用机制及与之相关的治疗方案进行总结,为肠道激素受体激动剂的研发提供思路。Receptor agonists developed based on intestinal hormones have been proven to be one of the effective means for treating obesity and type 2 diabetes,with promising application prospects.Their therapeutic mechanisms involve regulating energy balance and improving pancreatic function,among other aspects.Intestinal hormones,as important substances for regulating energy balance,play a regulatory role in body weight and glucostasis through different signaling pathways in various tissues,indicating that intestinal hormones have complex regulatory mechanisms in the development of obesity and type 2 diabetes.Therefore,research on intestinal hormones as treatment targets for obesity and type 2 diabetes has attracted widespread attention.This article summarizes the current mechanism of action of intestinal hormones and related treatment plans,providing ideas for the development of intestinal hormone receptor agonists.

关 键 词：肠道激素 肥胖 2型糖尿病 能量平衡 

分 类 号：R587.1[医药卫生—内分泌] R589.2[医药卫生—内科学]